Myopic Macular Degeneration market across the 7MM is projected to reach USD 837 million by 2034, estimates DelveInsight

In 2022, the Myopic Macular Degeneration market across the 7MM was valued at approximately USD 734 million, largely driven by anti-VEGF therapies and standard care. The Myopic Macular Degeneration market is expected to grow gradually through 2034, constrained by a limited pipeline of emerging treatments. Japan accounts for the largest share of diagnosed cases (49%), followed by the United States (27%). Females are disproportionately affected across the 7MM, potentially due to hormonal, genetic, or environmental factors. Myopic choroidal neovascularization (mCNV) represented about 5% of total diagnosed cases in 2022. Key players such as Roche, Bayer, and Regeneron Pharmaceuticals continue to develop innovative therapies to address unmet clinical needs and enhance patient outcomes.

DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034" report provides a comprehensive analysis of Myopic Macular Degeneration, covering disease overview, historical and projected epidemiology, along with market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Gain detailed insights into the dynamic Myopic Macular Degeneration market landscape. Download a free sample report here: https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Myopic Macular Degeneration Market Report
• According to DelveInsight's estimates, nearly 4.1 million diagnosed prevalent cases of Myopic Macular Degeneration were reported across the 7MM in 2022, with the patient pool expected to expand throughout the forecast timeframe.
• In the United States, approximately 1.1 million individuals were diagnosed with Myopic Macular Degeneration in 2022, and this number is anticipated to grow at a steady CAGR during the study period (2020-2034).
• Among all 7MM regions, Japan recorded the largest diagnosed patient population, accounting for nearly 2 million cases in 2022, with projections indicating further growth between 2023 and 2034.
• Within EU4 and the UK, France reported the highest diagnosed prevalent population of Myopic Macular Degeneration at nearly 0.27 million cases in 2022, followed by Germany and the UK, while Spain represented the lowest share during the same year.
• Gender-based analysis by DelveInsight in 2022 showed that diagnosed Myopic Macular Degeneration cases in the 7MM comprised approximately 39% males and 61% females.
• Major players operating in the Myopic Macular Degeneration market include Roche, Bayer, Regeneron Pharmaceuticals, among others.
• Key therapies under focus for Myopic Macular Degeneration include Ranibizumab injection (0.5 mg), VEGF Trap-Eye (BAY86-5321), EYLEA (aflibercept), VABYSMO (faricimab), and additional treatment options.

Explore regional treatment pathways and patient journeys for Myopic Macular Degeneration across major geographies. Access your complimentary sample report here:
https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Myopic Macular Degeneration Epidemiology Segmentation Across the 7MM
• Total diagnosed prevalent cases of Myopic Macular Degeneration
• Gender-wise diagnosed prevalent cases of Myopic Macular Degeneration
• Overall diagnosed prevalent Myopic Macular Degeneration population

Download the full report to gain insights into the key drivers shaping Myopic Macular Degeneration epidemiological trends: https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Myopic Macular Degeneration Approved Therapies
• EYLEA (aflibercept): Bayer / Regeneron Pharmaceuticals
EYLEA is an injectable anti-VEGF therapy designed for ocular use. It functions by inhibiting VEGF-A and placental growth factor (PLGF) from binding to their natural receptors, as demonstrated in earlier clinical studies. While the therapy exhibits a strong safety profile, its market performance and cost-effectiveness relative to alternative treatments remain key considerations. Currently, EYLEA is the only approved treatment for myopic choroidal neovascularization (mCNV) in Japan and Europe with an active patent, allowing it to maintain market leadership without biosimilar competition.

Myopic Macular Degeneration Emerging Therapies
• VABYSMO (faricimab): Roche
VABYSMO (faricimab) is the first bispecific antibody developed for intraocular use. It simultaneously targets angiopoietin-2 (Ang-2) and VEGF-A, thereby inhibiting two critical signaling pathways involved in several vision-threatening retinal diseases. Although faricimab is not officially listed in Roche's pipeline for mCNV treatment, a Phase III clinical trial is registered on ClinicalTrials.gov and is currently marked as "not yet recruiting."

Access in-depth insights into Myopic Macular Degeneration market trends and long-term forecasts with DelveInsight: https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Myopic Macular Degeneration Key Companies
Prominent companies active in the Myopic Macular Degeneration market include Roche, Bayer, Regeneron Pharmaceuticals, and others.

Myopic Macular Degeneration Market Outlook
Myopic maculopathy also referred to as Myopic Macular Degeneration or myopic retinopathy-includes conditions such as macular atrophy, lacquer cracks, and myopic choroidal neovascularization (mCNV). Disease progression is closely linked to aging and increased axial length of the eye. Preventive strategies, including low-dose atropine therapy and optical interventions, aim to slow myopia progression. Currently, treatment options remain limited, with effective therapies available only for mCNV, underscoring the urgent need for novel treatment approaches. Existing treatment paradigms mirror those used in wet age-related macular degeneration (AMD), primarily relying on anti-VEGF agents such as LUCENTIS (off-patent) and EYLEA.

Myopic Macular Degeneration Treatment Market Landscape
The Myopic Macular Degeneration treatment market is expected to witness consistent growth, fueled by the increasing global prevalence of high myopia particularly in Asian populations which significantly raises the risk of MMD-related vision impairment. At present, intravitreal anti-VEGF therapies, including ranibizumab, aflibercept, and bevacizumab, dominate the mCNV treatment space due to their established clinical efficacy. However, the market is gradually transitioning toward advanced biologics, longer-acting formulations, and innovative drug delivery systems designed to minimize treatment frequency and enhance patient adherence.

Discover comprehensive Myopic Macular Degeneration market insights and forecasts with DelveInsight:
https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Myopic Macular Degeneration Market Report
• Geographical Coverage: 7MM
• Study Duration: 2020-2034
• Key Companies: Roche, Bayer, Regeneron Pharmaceuticals, and others
• Therapies Assessed: Ranibizumab injection (0.5 mg), VEGF Trap-Eye (BAY86-5321), EYLEA (aflibercept), VABYSMO (faricimab), and additional therapies
• Therapeutic Evaluation: Currently marketed and emerging Myopic Macular Degeneration therapies
• Market Dynamics: Key growth drivers and market restraints
• Competitive Intelligence: SWOT analysis, PESTLE analysis, Porter's Five Forces, BCG Matrix, and market entry strategies
• Additional Insights: Unmet needs, Key Opinion Leader (KOL) perspectives, analyst viewpoints, market access, and reimbursement analysis

Unlock actionable insights with DelveInsight's in-depth Myopic Macular Degeneration market report:
https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Key Insights
2. Introduction to the Myopic Macular Degeneration Market Report
3. Myopic Macular Degeneration Market Overview at a Glance
4. Myopic Macular Degeneration Epidemiology and Market Research Methodology
5. Executive Summary
6. Key Events
7. Disease Background and Overview
8. Myopic Macular Degeneration Epidemiology and Patient Population
9. Myopic Macular Degeneration Patient Journey
10. Myopic Macular Degeneration Marketed Therapies
11. Myopic Macular Degeneration Emerging Therapies
12. Myopic Macular Degeneration Market Analysis
13. Key Opinion Leader Perspectives
14. SWOT Analysis
15. Myopic Macular Degeneration Unmet Needs
16. Myopic Macular Degeneration Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.